中国麻风皮肤病杂志 ›› 2019, Vol. 35 ›› Issue (2): 70-72.doi: 10.12144/zgmfskin201902070

• 论著 • 上一篇    下一篇

依巴斯汀三倍剂量治疗轻中度特应性皮炎的疗效和安全性

钱佳丽  何静岩  孙丽蕴   

  1. 北京中医医院顺义医院皮肤科，北京,101300
  • 出版日期:2019-02-20 发布日期:2019-03-07
  • 通讯作者: 孙丽蕴,E-mail: doctorsunny@sina.cn

Efficacy and safety of three-times dose of Ebastine in the treatment of mild to moderate atopic dermatitis

QIAN Jiali, HE Jingyan, SUN Liyun   

  1. Department of Dermatology, Shunyi Hospital, Beijing Chinese Medicine Hospital, Beijing 101300, China
  • Online:2019-02-20 Published:2019-03-07
  • Contact: SUN Liyun, E-mail: doctorsunny@sina.cn

PDF (PC)

180

摘要： 目的：评价依巴斯汀三倍剂量治疗特应性皮炎的有效性和安全性。方法：选取轻度至中度的特应性皮炎患者为研究对象，随机分为观察组和对照组。观察组口服依巴斯汀片30 mg/d联合医用凡士林外用，对照组口服依巴斯汀片10 mg/d联合医用凡士林外用，观察两组患者在28天治疗后的瘙痒评分、SCORAD总分、临床总有效率以及发生的不良反应。结果：共收集患者128例，其中观察组和对照组各64例，观察组的瘙痒评分、SCORAD总分分别为3.02±1.19和21.83±3.05均显著低于对照组的6.77±1.33和29.28±4.91（P<0.05）；观察组临床总有效率为93.33%高于对照组的68.75%，差异有统计学意义（P<0.05）；观察组不良反应发生率为6.3%，对照组为9.4%，两组不良反应比较无统计学差异（P＞0.05）。结论：与常规剂量的依巴斯汀比较，30 mg/d的依巴斯汀治疗特应性皮炎疗效优于10 mg/d，不良反应无明显差异。

关键词: 特应性皮炎, 依巴斯汀, 疗效, 安全性

Abstract: Objective: To evaluate the efficacy and safety of three-times the dose of Ebastine in the treatment of the patients with atopic dermatitis (AD). Methods: The patients with mild to moderate AD were collected and were divided into the observation group and the control group randomly. The patients in the observation group were treated with Ebastine 30mg/d，orally and topical Vaseline and those in the control group was treated with Ebastine 10mg/d, orally and topical Vaseline. After 28 days of the treatment, the itching score, SCORAD score, total clinical efficacy rate and adverse reaction were assessed. Results: A total of 128 patients were collected (64 patients in each group). The itching score and SCORAD in the observation group were 3.02±1.19 and 21.83±3.05, which were lower than those in the control group (6.77±1.33 and 29.28±4.91), with significant differences (P<0.05). The efficacy in the observation group was 93.33%, which was higher than that in the control group (68.75%), with a significant difference (P<0.05). The adverse reaction rate in the observation group and control group were 6.3% and 9.4% respectively, with no significant difference (P>0.05). Conclusion: 30mg/d Ebastine in the treatment of atopic dermatitis is more effective than 10mg/d, with similar adverse reaction.

Key words: atopic dermatitis, ebastine, efficacy, safety